§ 1702.2 Procedural requirements and recommendations.

(a) * * *

(1) Be mailed to the Office of the Secretary, Consumer Product Safety Commission, Washington, DC 20207, or delivered to the Office of the Secretary, Consumer Product Safety Commission, 4330 East West Highway, Bethesda, MD 20814.

* * * * *

Sadye E. Dunn,

Secretary, Consumer Product Safety Commission.

[FR Doc. 97-23498 Filed 9-3-97; 8:45 am] BILLING CODE 6355-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Tetracycline Hydrochloride Soluble Powder

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Med-Pharmex, Inc. The ANADA provides for oral use of tetracycline hydrochloride soluble powder in the drinking water of swine and calves for control and treatment of certain diseases caused by pathogens susceptible to tetracycline, and of chickens and turkeys for control of certain diseases caused by pathogens susceptible to tetracycline.

EFFECTIVE DATE: September 4, 1997. **FOR FURTHER INFORMATION CONTACT:** Lonnie W. Luther, Center For Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0209.

SUPPLEMENTARY INFORMATION: Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA 91767–1861, filed ANADA 200–234, which provides for oral use of tetracycline hydrochloride soluble powder in the drinking water of calves, swine, chickens, and turkeys, as follows: (1) For calves for control and treatment of bacterial enteritis (scours) caused by *Escherichia coli*, and bacterial pneumonia (shipping fever complex) associated with *Pasteurella* spp., *Actinobacillus pleuropneumoniae* (*Hemophilus* spp.), and *Klebsiella* spp.

susceptible to tetracycline; (2) for swine for control and treatment of bacterial enteritis (scours) caused by E. coli, and bacterial pneumonia associated with Pasteurella spp., Actinobacillus pleuropneumoniae (Hemophilus spp.), and Klebsiella spp. susceptible to tetracycline; (3) for chickens for control of chronic respiratory disease (CRD or air-sac disease) caused by Mycoplasma gallisepticum and E. coli; infectious synovitis caused by M. synoviae susceptible to tetracycline; and (4) for turkeys for control of infectious synovitis caused by M. synoviae and bluecomb (transmissible enteritis or coronaviral enteritis) complicated by bacterial organisms susceptible to tetracycline.

Approval of Med-Pharmex's ANADA 200–234 tetracycline hydrochloride soluble powder is as a generic copy of Fermenta's NADA 65–496 tetracycline hydrochloride soluble powder. ANADA 200–234 is approved as of July 22, 1997, and the regulations are amended in 21 CFR 520.2345d(a)(1) to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.24(d)(1)(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b).

§ 520.2345d [Amended]

2. Section 520.2345d *Tetracycline* hydrochloride soluble powder is amended in paragraph (a)(1) by removing "047864, 000010, 057561, and 059130" and adding in its place "047864, 051259, 054273, 057561, and 059130".

Dated: August 22, 1997.

Michael J. Blackwell,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. 97–23372 Filed 9–3–97; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Clindamycin Hydrochloride Liquid

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Phoenix Scientific, Inc. The ANADA provides for veterinary prescription use in dogs of clindamycin hydrochloride liquid for therapy of wounds, abscesses, and dental infections, and therapy of osteomyelitis.

EFFECTIVE DATE: September 4, 1997. **FOR FURTHER INFORMATION CONTACT:** Lonnie W. Luther, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0209.

SUPPLEMENTARY INFORMATION: Phoenix Scientific, Inc., 3915 South 48th St. Terrace, P.O. Box 6457, St. Joseph, MO 64506–0457, filed ANADA 200–193 that provides for veterinary prescription use in dogs of clindamycin hydrochloride liquid for therapy of wounds, abscesses, and dental infections when administered orally at 2.5 milligrams per pound (mg/lb) every 12 hours, and for therapy of osteomyelitis when administered orally at 5.0 mg/lb every 12 hours.

Phoenix Scientific, Inc.'s, ANADA 200–193 clindamycin hydrochloride liquid is approved as a generic copy of Pharmacia & Upjohn's NADA 135–940 Antirobe Aquadrops®. The ANADA is approved as of August 1, 1997, and the regulations are amended in 21 CFR 520.447(b) to reflect the approval. The